RxDoctor Payments Data

John McNeill, DO

Emergency Medicine · Victoria, TXNPI 1205812898

Payments from drug & device makers

$1,409in general payments, 2019–2025

Across 80 payments — averaging $17.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$307
  • Astellas Pharma US Inc$205
  • Johnson & Johnson$123
  • Antares Pharma, Inc.$117
  • AstraZeneca$77
  • Amarin Pharma, Inc.$73
  • plus $507 from 14 others

What the payments were for

  • Food & beverage$1,23488%
  • Education$17512%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,409 in reported general payments places this provider in the 95th percentile of 3,952 emergency medicine providers in Texas.

See all emergency medicine providers in Texas

Medicare billing

Part B allowed, 2024
$128,606
Medicare patients
690
Services billed
1,292

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide75$104,874
EliquisApixaban90$101,588
JanuviaSitagliptin Phosphate49$59,532
TrulicityDulaglutide33$44,893
JardianceEmpagliflozin47$41,237
MounjaroTirzepatide26$38,056
Tresiba Flextouch U-200Insulin Degludec30$31,450
TradjentaLinagliptin21$23,751
FarxigaDapagliflozin Propanediol15$19,180
JanumetSitagliptin Phos/Metformin Hcl16$13,130
XareltoRivaroxaban11$12,796
GlyxambiEmpagliflozin/Linagliptin12$7,217
Janumet XrSitagliptin Phos/Metformin Hcl11$6,199
Levothyroxine Sodium545$6,126
Xtampza ErOxycodone Myristate12$4,187

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Premarin$41$105,109105 claims
Novo NordiskOzempic$307$104,87475 claims
Lilly USA, LLCTrulicity, Mounjaro$14$82,94959 claims
MerckJanuvia, Janumet, Janumet Xr$20$78,86076 claims
AstraZenecaFarxiga$77$19,18015 claims
Johnson & JohnsonXarelto$123$12,79611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,952 emergency medicine providers in Texas.

Other emergency medicine in Victoria

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →